Actinium Pharmaceuticals, Inc. – ‘10-Q’ for 9/30/18 – ‘EX-101.CAL’

On:  Friday, 11/9/18, at 5:01pm ET   ·   For:  9/30/18   ·   Accession #:  1213900-18-15315   ·   File #:  1-36374

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    324K 
 2: EX-4.1      Amendment to Actinium Pharmaceuticals, Inc.         HTML     17K 
                Warrant to Purchase Common Stock, Dated November                 
                8, 2018 Issued to Amosan LLC.                                    
 3: EX-4.2      Amendment to Actinium Pharmaceuticals, Inc.         HTML     17K 
                Warrant to Purchase Common Stock, Dated November                 
                8, 2018 Issued to Carnegie Hill Partners                         
 4: EX-4.3      Amendment to Actinium Pharmaceuticals, Inc.         HTML     17K 
                Warrant to Purchase Common Stock, Dated November                 
                8, 2018 Issued to Bioche Asset Management, LLC.                  
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     20K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     20K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     16K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     16K 
15: R1          Document and Entity Information                     HTML     42K 
16: R2          Consolidated Balance Sheets (Unaudited)             HTML     79K 
17: R3          Consolidated Balance Sheets (Unaudited)             HTML     37K 
                (Parenthetical)                                                  
18: R4          Consolidated Statements of Operations (Unaudited)   HTML     53K 
19: R5          Consolidated Statements of Cash Flows (Unaudited)   HTML     63K 
20: R6          Description of Business and Summary of Significant  HTML     58K 
                Accounting Policies                                              
21: R7          Derivative Liabilities                              HTML     35K 
22: R8          Commitments and Contingencies                       HTML     29K 
23: R9          Equity                                              HTML     46K 
24: R10         Supplemental Disclosure of Cash Flow Information    HTML     17K 
25: R11         Subsequent Events                                   HTML     26K 
26: R12         Description of Business and Summary of Significant  HTML     88K 
                Accounting Policies (Policies)                                   
27: R13         Description of Business and Summary of Significant  HTML     33K 
                Accounting Policies (Tables)                                     
28: R14         Derivative Liabilities (Tables)                     HTML     35K 
29: R15         Equity (Tables)                                     HTML     35K 
30: R16         Description of Business and Summary of Significant  HTML     23K 
                Accounting Policies (Details)                                    
31: R17         Description of Business and Summary of Significant  HTML     19K 
                Accounting Policies (Details 1)                                  
32: R18         Description of Business and Summary of Significant  HTML     29K 
                Accounting Policies (Details 2)                                  
33: R19         Description of Business and Summary of Significant  HTML     32K 
                Accounting Policies (Details Textual)                            
34: R20         Derivative Liabilities (Details)                    HTML     22K 
35: R21         Derivative Liabilities (Details 1)                  HTML     36K 
36: R22         Derivative Liabilities (Details Textual)            HTML     30K 
37: R23         Commitments and Contingencies (Details)             HTML     46K 
38: R24         Equity (Details)                                    HTML     54K 
39: R25         Equity (Details 1)                                  HTML     63K 
40: R26         Equity (Details Textual)                            HTML    100K 
41: R27         Subsequent Events (Details)                         HTML     53K 
43: XML         IDEA XML File -- Filing Summary                      XML     68K 
42: EXCEL       IDEA Workbook of Financial Reports                  XLSX     37K 
 9: EX-101.INS  XBRL Instance -- atnm-20180930                       XML    503K 
11: EX-101.CAL  XBRL Calculations -- atnm-20180930_cal               XML     82K 
12: EX-101.DEF  XBRL Definitions -- atnm-20180930_def                XML    324K 
13: EX-101.LAB  XBRL Labels -- atnm-20180930_lab                     XML    569K 
14: EX-101.PRE  XBRL Presentations -- atnm-20180930_pre              XML    449K 
10: EX-101.SCH  XBRL Schema -- atnm-20180930                         XSD     93K 
44: ZIP         XBRL Zipped Folder -- 0001213900-18-015315-xbrl      Zip     72K 

‘EX-101.CAL’   —   XBRL Calculations — atnm-20180930_cal

This Exhibit is an XBRL XML File.

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/25/22  Actinium Pharmaceuticals, Inc.    10-K       12/31/21   56:4.2M                                   EdgarAgents LLC/FA
 3/31/21  Actinium Pharmaceuticals, Inc.    10-K       12/31/20   56:3.5M                                   EdgarAgents LLC/FA